Trials / Terminated
TerminatedNCT01722292
A Study of LY2940680 in Small Cell Lung Cancer
A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination With Carboplatin and Etoposide Followed by LY2940680 Versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients With Extensive-Stage Small Cell Lung Cancer
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find a recommended dose of LY2940680 that can be safely given in combination with etoposide and carboplatin followed by LY2940680 alone in participants with extensive-disease small cell lung cancer. The study will also compare progression-free survival in participants who are administered etoposide, carboplatin and LY2940680 followed by LY2940680 alone versus etoposide, carboplatin, and placebo followed by placebo alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY2940680 | Administered orally |
| DRUG | Carboplatin | Administered IV |
| DRUG | Etoposide | Administered IV |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2015-02-01
- Completion
- 2015-02-01
- First posted
- 2012-11-06
- Last updated
- 2018-12-28
- Results posted
- 2018-12-28
Locations
14 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT01722292. Inclusion in this directory is not an endorsement.